{"id":12725,"date":"2021-07-22T18:44:43","date_gmt":"2021-07-22T13:14:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12725"},"modified":"2021-10-12T10:33:02","modified_gmt":"2021-10-12T05:03:02","slug":"recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","title":{"rendered":"BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera\u2019s nerve implant gets a $65M boost Rivus\u2019 therapy nabs $35M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d24c1fd9117\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d24c1fd9117\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\/#BlueRock_Therapeutics_secures_FDA_fast_track_for_Parkinsons_disease_cell_therapy\" >BlueRock Therapeutics secures FDA fast track for Parkinson\u2019s disease cell therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\/#Omniscient_Neurotechnology_rakes_in_USD_29_Million_to_map_out_the_electrical_networks\" >Omniscient Neurotechnology rakes in USD 29 Million to map out the electrical networks&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\/#Neuspera_Medical_scores_USD_65_Million_for_the_nerve-stimulating_implant_to_treat_overactive_bladder\" >Neuspera Medical scores USD 65 Million for the nerve-stimulating implant to treat overactive bladder<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\/#Rivus_fat-trimming_therapy_nabs_USD_35_Million_to_harness_biology_against_a_host_of_diseases\" >Rivus\u2019 fat-trimming therapy nabs USD 35 Million to harness biology against a host of diseases<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BlueRock_Therapeutics_secures_FDA_fast_track_for_Parkinsons_disease_cell_therapy\"><\/span><strong>BlueRock Therapeutics secures FDA fast track for Parkinson\u2019s disease cell therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study.<\/p>\n\n\n\n<p>This early-stage trial is set to enroll ten patients across the US and Canada, with its primary aim to evaluate the safety and tolerability of DA01 cell transplantation at one year post-transplant.<\/p>\n\n\n\n<p>As a secondary aim, BlueRock will evaluate the evidence of transplanted cell survival and motor effects at one- and two years post-transplant and assess the continued safety and tolerability at two years, as well as the feasibility of transplantation.<\/p>\n\n\n\n<p>Joachim Fruebis, chief development officer of BlueRock, said that receiving fast track designation from the FDA is a crucial step, which will help them further progress clinical development of their DA01 <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">cell therapy<\/a><\/strong> approach for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson\u2019s disease<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<p>In 2019, Bayer bought out its private equity partner Versant Ventures and its founders in BlueRock Therapeutics for USD 240 million, three years after setting up the company.<\/p>\n\n\n\n<p>The decision gave Bayer complete control of BlueRock\u2019s cell therapy pipeline, headed by DA01 and spanning various diseases in the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neurovascular-devices-interventional-neurology-market\">neurology<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/interventional-cardiology-devices-market\">cardiology<\/a><\/strong>, and immunology categories.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Omniscient_Neurotechnology_rakes_in_USD_29_Million_to_map_out_the_electrical_networks\"><\/span><strong>Omniscient Neurotechnology rakes in USD 29 Million to map out the electrical networks&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Omniscient Neurotechnology, an Australian startup is developing artificial intelligence software to assess the networks of electrical connections unique to every person\u2019s brain.<\/p>\n\n\n\n<p>With the recent close of its series B funding round, which brought in about USD 29.3 million, the company hopes to cross the vital line between developing high-potential, but still largely theoretical, technology and weaving those methods into actual clinical use.<\/p>\n\n\n\n<p>To do so, Omniscient will utilize the financing to expand market access for its existing brain-mapping platforms, in part by increasing its global sales team. It will also hasten its R&amp;D pipeline and add to the science and engineering teams behind those efforts to advance neurological research and progress new hardware.<\/p>\n\n\n\n<p>So far, Omniscient has built two platforms to map out and assess the brain\u2019s electrical networks. Both use machine learning to draw this information from MRI scans.<\/p>\n\n\n\n<p>Infinitome proffers up analysis for use in research settings, with a platform for studies that aim to comprehend better how diseases such as <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market\">epilepsy<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market\">schizophrenia<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">multiple sclerosis<\/a><\/strong>, and others impact the brain&#8217;s electrical connections and potentially help distinguish valuable significant biomarkers.<\/p>\n\n\n\n<p>Quicktome, meanwhile, was designed for clinical use. The platform offers neurosurgeons a clearer picture of the inner workings of their patients\u2019 brains ahead of major operations, mapping out the areas responsible for speech, movement, and thought. Eventually, with the help of brain-mapping AI, Omniscient aims to offer surgeons a way to perform more precise and safer procedures preserving essential functions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neuspera_Medical_scores_USD_65_Million_for_the_nerve-stimulating_implant_to_treat_overactive_bladder\"><\/span><strong>Neuspera Medical scores USD 65 Million for the nerve-stimulating implant to treat overactive bladder<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Neuspera Medical\u2019s miniaturized neuromodulation device is making an outsized influence on the field of medical technology.<\/p>\n\n\n\n<p>The device is implanted into the body to instigate nerves linked to chronic illnesses, inhibiting the signals that may result in painful symptoms. The <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\">neuromodulation therapy<\/a><\/strong> is managed by an external wireless controller, which can transmit electromagnetic pulses through skin, fat, muscle, and bones to trigger the indicated nerves when worn close to the body.<\/p>\n\n\n\n<p>The system has now received a significant vote of confidence in the form of a USD 65 million Series C funding round. That is more than double Neuspera\u2019s early 2019 series B, which brought in USD 26 million across two tranches and nearly triples the company\u2019s lifetime funding. The round was co-led by Vertex Ventures HC and Treo Ventures, each of which will send representatives to Neuspera\u2019s board of directors.<\/p>\n\n\n\n<p>The bulk of the financing will be funneled toward the California-based startup\u2019s ongoing clinical trial exploring the ability of the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\">neuromodulation system<\/a><\/strong> for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/urinary-incontinence-market\">urinary urgency incontinence treatment<\/a><\/strong>; its first indicated use.<\/p>\n\n\n\n<p>To address symptoms of overactive bladder, the receiver device is implanted into the lower back, adjacent to the sacral nerve. Once in place, the external controller wirelessly emits electromagnetic waves to the receiver, which sends signals to the nerves and the brain to help normalize bladder function.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rivus_fat-trimming_therapy_nabs_USD_35_Million_to_harness_biology_against_a_host_of_diseases\"><\/span><strong>Rivus\u2019 fat-trimming therapy nabs USD 35 Million to harness biology against a host of diseases<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Rivus Pharmaceuticals is going after the diseases:- <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">Type 2 diabetes<\/a><\/strong>; <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-hypertriglyceridemia-shtg-market\">severe hypertriglyceridemia (SHTG);<\/a><\/strong> <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">non-alcoholic steatohepatitis (NASH)<\/a><\/strong>; and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-market\">heart failure<\/a><\/strong> with preserved ejection fraction (HFpEF). These are just the start for the tiny biotech as it nabs USD 35 million for a big push into the clinic.<\/p>\n\n\n\n<p>The series A for the Charlottesville, Virginia-based startup was co-led by Longitude Capital and Medicxi, with help from RxCapital. It looks to carry on with a new class of oral, once-daily, small molecule drugs called Controlled Metabolic Accelerators (CMAs).<\/p>\n\n\n\n<p>These are designed to enhance cellular metabolism and treat the underlying cause of metabolic and cardiovascular disease, comprising the blockbuster potential <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-alcoholic-fatty-liver-disease-nafld-market\">fatty liver disease NASH<\/a><\/strong> and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight\">obesity <\/a><\/strong>and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-hypertension-market\">hypertension<\/a><\/strong>, among others.<\/p>\n\n\n\n<p>Allen Cunningham, President, and CEO of Rivus Pharmaceuticals said that the CMAs are made to effectively aim at the root cause of these diseases by enhancing cellular metabolism with the potential to halt the progress of, or even reverse, these diseases. CMAs work as a new approach to stimulate mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BlueRock Therapeutics secures FDA fast track for Parkinson\u2019s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its primary aim to evaluate the safety and tolerability of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":12728,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[420,639],"industry":[17225],"therapeutic_areas":[17235,17240,17230,17245],"class_list":["post-12725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Neuspera Bags $65M | Omniscient Rakes in $29M | Rivus Nabs $35M<\/title>\n<meta name=\"description\" content=\"Neuspera bags $65M for the nerve-stimulating implant; BlueRock secures FDA fast track; Omniscient rakes in $29M; Rivus\u2019 therapy nabs $35M...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuspera Bags $65M | Omniscient Rakes in $29M | Rivus Nabs $35M\" \/>\n<meta property=\"og:description\" content=\"Neuspera bags $65M for the nerve-stimulating implant; BlueRock secures FDA fast track; Omniscient rakes in $29M; Rivus\u2019 therapy nabs $35M...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T13:14:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T05:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neuspera Bags $65M | Omniscient Rakes in $29M | Rivus Nabs $35M","description":"Neuspera bags $65M for the nerve-stimulating implant; BlueRock secures FDA fast track; Omniscient rakes in $29M; Rivus\u2019 therapy nabs $35M...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","og_locale":"en_US","og_type":"article","og_title":"Neuspera Bags $65M | Omniscient Rakes in $29M | Rivus Nabs $35M","og_description":"Neuspera bags $65M for the nerve-stimulating implant; BlueRock secures FDA fast track; Omniscient rakes in $29M; Rivus\u2019 therapy nabs $35M...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-07-22T13:14:43+00:00","article_modified_time":"2021-10-12T05:03:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus","name":"Neuspera Bags $65M | Omniscient Rakes in $29M | Rivus Nabs $35M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus.jpg","datePublished":"2021-07-22T13:14:43+00:00","dateModified":"2021-10-12T05:03:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Neuspera bags $65M for the nerve-stimulating implant; BlueRock secures FDA fast track; Omniscient rakes in $29M; Rivus\u2019 therapy nabs $35M...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bluerock-omniscient-neuspera-rivus#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus.jpg","width":772,"height":482,"caption":"recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/22184419\/recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jul 22, 2021","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Jul 22, 2021 6:44 pm","modified":"Updated on Oct 12, 2021 10:33 am"},"featured_img_caption":"recent-pharma-news-updates-for-bluerock-omniscient-neuspera-rivus","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12725"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12728"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12725"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12725"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}